NEW YORK – Tempus on Thursday said it has expanded its previous collaboration with Takeda to use real-world data to improve oncology research and development.
Under the new agreement, Takeda will use Tempus' multimodal real-world datasets and biological modeling capabilities to further advance its cancer therapeutics pipeline. Researchers from Takeda will utilize Tempus' Lens analytics platform to access de-identified patient records, as well as a suite of artificial intelligence-based tools to "accelerate critical insights for Takeda's drug development efforts," Tempus said in a statement.
Takeda's pipeline includes antibody-drug conjugates, small molecules, bispecific antibodies, and gamma delta T-cell therapies.
The two firms have also been collaborating on a multiphase biological modeling project using a large repository of patient-derived tumor organoids. Through DNA sequencing assays, the organoid models can be genetically linked to Tempus' multimodal dataset, which could potentially improve predictions of a drug's effectiveness, Tempus said. The company is working with Takeda on a panel of 60 organoids across 10 cancer indications to evaluate several preclinical drug candidates.
"The results we’ve seen thus far demonstrate how the collaboration between the Takeda and Tempus teams can assist in efforts to accelerate Takeda’s growing oncology therapeutic pipeline, which may lead to the next generation of cancer treatments," Tempus Chief Operating Officer Ryan Fukushima said in a statement.